Tuition Hikes and International Student Visa Restrictions Fuel Demand for Investment Migration Programs
2.9.2019 19:44:00 EEST | Business Wire | Press release
As global headlines are dominated by the effects of changing immigration policies in the UK and the US, there is one consequence that has gone largely unnoticed: a significant decline in international student numbers. Latest statistics show that top universities have seen international enrollment figures drop significantly in response to new restrictions on student visas in the US, uncertainty over Brexit and the rights of EU citizens in the UK, and tuition hikes in both countries.
Seeking to avoid these pitfalls, high-net-worth individuals (HNWIs) are pursuing alternative residence or citizenship rights that will allow their children to fulfil their academic aspirations without becoming entangled in risky or unpredictable visa application processes.
Dr. Juerg Steffen, CEO of investment migration firm Henley & Partners, says education is a fundamental priority for most clients. “There are many reasons for acquiring alternative citizenship or residence, but ultimately, it comes down to long-term stability and security – a classic investment hedge against potential volatility. The dramatically expanded education options that open up by having alternative citizenship or residence in a desirable location is often a decisive factor for families when they are considering making this kind of investment.”
The UK Investor Immigration Program is ideal for investors seeking to take advantage of the UK’s excellent primary, secondary, and tertiary education services. As noted by the Knight Frank Global Wealth Report, although Australia, Canada, Switzerland, the US, and a number of other countries all attract students from overseas, the UK’s private boarding schools are still seen as the gold standard by many. At the tertiary level, the Oxford and Cambridge universities are currently ranked number one and two in the world by Times Higher Education, which provides the definitive list of the world’s best universities.
Of the universities in mainland Europe, revered institutions such as Humboldt University of Berlin, Sorbonne University in Paris, and the University of Amsterdam continue to draw wealthy international students, attracted by both the peerless quality of education on offer and the experience of student life in a European capital. For investors wanting to give their children access to these kinds of opportunities, a key advantage of European universities is that fees for EU citizens are much lower than they are for non-EU citizens — up to 50% or more. For an investment of between EUR 1 million and EUR 2.15 million, Malta and Cyprus offer the most popular citizenship-by-investment programs in the EU at present.
Across the Atlantic, the US EB-5 Immigrant Investor Program is an attractive option for those who have their sights set on an American education. The program offers permanent residence in exchange for an investment of USD 500,000 to USD 1 million. The Australia Residence-by-Investment Program is another potential avenue to pursue. Overall, the country is renowned for its education system — one of many reasons it remains the top destination of choice for HNWIs looking to resettle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190902005238/en/
Contact information
Media
Sarah Nicklin
Senior Group PR Manager
sarah.nicklin@henleyglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti
Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti
4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a
4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a
LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 05:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for a global leader in healthcare services. This resulted in faster time to market, modern scalable ecosys
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
